PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM) Conference Paper uri icon

authors

  • Reardon, David
  • Kaley, Thomas
  • Dietrich, Jorg
  • Clarke, Jennifer L
  • Dunn, Gavin P
  • Lim, Michael
  • Cloughesy, Timothy
  • Gan, Hui K
  • Park, Andrew
  • Schwarzenberger, Paul
  • Ricciardi, Toni
  • Macri, Mary
  • Ryan, Aileen
  • Venhaus, Ralph

publication date

  • November 1, 2017